3-hydroxy-3-(2-methoxyphenyl)-5-methyl-1,3-dihydro-2H-indol-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-hydroxy-3-(2-methoxyphenyl)-5-methyl-1,3-dihydro-2H-indol-2-one
• 英文别名: 3-hydroxy-3-(2-methoxyphenyl)-5-methyl-1H-indol-2-one
• 化学式: C₁₆H₁₅NO₃
• 分子量: 269.29
• InChiKey: ZMGGVQFDSUTQAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  镁 、 2-溴苯甲醚 、 5-甲基靛红 、 氯化铵 、 四氢呋喃 在 氩 、 乙酸乙酯 、 水 、 氯化钠 、 Sodium sulfate-III 作用下， 反应 3.0h， 以to give 9 g of the expected product的产率得到3-hydroxy-3-(2-methoxyphenyl)-5-methyl-1,3-dihydro-2H-indol-2-one
  参考文献：
  名称：

  Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them

  摘要：

  本发明涉及以下式子的化合物1，以及可能的与矿物质或有机酸形成的盐，以及溶剂化合物和/或水合物，这些化合物对精氨酸加压素的V1b受体或V1b和V1a受体都具有亲和力和选择性。本发明还涉及制备它们的方法，有用于制备它们的式子(II)的中间体化合物，含有它们的制药组合物以及它们用于制备药物的用途。

  公开号：

  US20040209938A1

文献信息

• 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle
  申请人：Sekiguchi Yoshinori

  公开号：US20080318923A1

  公开（公告）日：2008-12-25

  It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

  旨在提供一种对与精氨酸加压素V1b受体相关的病理状况具有疗效的药物。更具体地说，旨在提供一种对抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、消化系统疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫疾病、脱发等具有治疗或预防作用的药物。经过深入研究，发现了一种新颖的1,3-二氢-2H-吲哚-2-酮化合物和与杂芳环融合的吡咯烷-2-酮化合物，它们是高度选择性的精氨酸加压素V1b受体拮抗剂，具有高代谢稳定性，表现出有利的血脑屏障穿透和高血浆浓度，从而实现了上述目标。
• Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors
  申请人：——

  公开号：US20030114683A1

  公开（公告）日：2003-06-19

  The invention relates to compounds of formula: 1 as well as the possible salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, which have affinity for and selectivity towards the V 1b receptors or towards both the V 1b and V 1a receptors of arginine-vasopressin. The invention also relates to the process for preparing them, to the intermediate compounds of formula (II) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for the preparation of medicinal products.

  本发明涉及以下化合物的公式：1，以及可能的与矿物质或有机酸盐和其溶剂和/或水合物，这些化合物具有亲和力和选择性，可以作用于精氨酸加压素的V1b受体或V1b和V1a受体。本发明还涉及制备它们的过程，有用于制备它们的公式（II）的中间化合物，包含它们的制药组合物以及它们用于制备药物的用途。
• 1,3-Dihydro-2h-indol-2-one derivative
  申请人：Kumagai Toshihito

  公开号：US20060276449A1

  公开（公告）日：2006-12-07

  A 1,3-dihydro-2H-indol-2-one derivative expressed by Formula 1 (wherein R 1 is a halogen atom, a C 1 to C 4 alkyl group, etc., and R 2 is a hydrogen atom, a halogen atom, etc., or R 2 is in the 6-position of the indol-2-one and R 1 and R 2 join together to form a C 3 to C 6 alkylene group, R 3 is a halogen atom, a hydroxyl group, etc., and R 4 is a hydrogen atom, a halogen atom, a C 1 to C 4 alkyl group, etc., or R 4 is in the 3-position of the phenyl and R 3 and R 4 join together to form a methylenedioxy group, R 5 is a hydrogen atom or a fluorine atom, R 6 is an ethylamino group, a dimethylamino group, etc., R 7 is a C 1 to C 4 alkoxy group, and R 8 is a C 1 to C 4 alkoxy group), or a pharmaceutically acceptable salt of this derivative. This is a novel compound that has antagonistic activity against an aruginine-vasopressin V1b receptor.

  公式1所表示的1,3-二氢吲哚-2-酮衍生物（其中R1是卤素原子、C1到C4烷基等，R2是氢原子、卤素原子等，或R2位于吲哚-2-酮的6位，且R1和R2结合形成C3到C6烷基，R3是卤素原子、羟基等，R4是氢原子、卤素原子、C1到C4烷基等，或R4位于苯环的3位，且R3和R4结合形成亚甲二氧基基团，R5是氢原子或氟原子，R6是乙基氨基基团、二甲基氨基基团等，R7是C1到C4烷氧基基团，R8是C1到C4烷氧基基团），或该衍生物的药学上可接受的盐。这是一种新型化合物，具有对抗arginine-vasopressin V1b受体的拮抗活性。
• NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Roux Richard

  公开号：US20070004703A1

  公开（公告）日：2007-01-04

  The invention relates to compounds of formula: as well as the possible salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, which have affinity for and selectivity towards the V 1b receptors or towards both the V 1b and V 1a receptors of arginine-vasopressin. The invention also relates to the process for preparing them, to the intermediate compounds of formula (II) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for the preparation of medicinal products.

  本发明涉及式的化合物：以及其可能的与矿物酸或有机酸形成的盐，以及其溶剂化合物和/或水合物，其具有亲和力和选择性，能够作用于精氨酸加压素的V1b受体或V1a和V1b受体。本发明还涉及用于制备它们的过程，有用于制备它们的式（II）的中间体化合物，含有它们的制药组合物以及它们用于制备药物的用途。
• 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them
  申请人：Sanofi-Aventis

  公开号：US07297692B2

  公开（公告）日：2007-11-20

  The invention relates to compounds of formula: as well as the possible salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, which have affinity for and selectivity towards the V1b receptors or towards both the V1b and V1a receptors of arginine-vasopressin. The invention also relates to the process for preparing them, to the intermediate compounds of formula (II) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for the preparation of medicinal products.

  本发明涉及公式的化合物：以及它们可能与矿物质或有机酸形成的盐，以及它们的溶剂化合物和/或水合物，它们具有亲和力和选择性，对精氨酸加压素的V1b受体或对V1b和V1a受体都具有选择性。本发明还涉及制备它们的过程，有用于制备它们的公式（II）的中间化合物，含有它们的制药组合物以及它们用于制备药物的使用。